Cipla Gets CDSCO Approval for Plazomicin Antibiotic for Urinary Tract Infections
By Rediff Money Desk, NEWDELHI Feb 26, 2024 19:18
Cipla receives CDSCO approval for plazomicin, a new intravenous antibiotic for treating complicated urinary tract infections (CUTI), including pyelonephritis.
![Cipla Gets CDSCO Approval for Plazomicin Antibiotic for Urinary Tract Infections](https://im.rediff.com/money/2023/aug/04cipla1.jpg)
Photograph: Danish Siddiqui/Reuters
New Delhi, Feb 26 (PTI) Drug major Cipla on Monday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to market the novel antibiotic plazomicin in India.
Plazomicin is a new intravenous (IV) aminoglycoside indicated for the treatment of Complicated Urinary Tract Infections (CUTI), including pyelonephritis.
"The introduction of plazomicin in India is an important step forward in bringing solutions that address the evolving healthcare challenges of our time," Cipla MD and Global CEO Umang Vohra said in a statement.
The company's focus remains on developing a robust antimicrobial portfolio, forging partnerships with thought leaders and industry alliances to ensure global access to antimicrobial drugs for a healthier life, he added.
Cipla USA, a subsidiary of Cipla, holds the patent for plazomicin sulfate, an intravenous aminoglycoside administered once daily.
The company possesses global rights for this molecule, excluding Greater China.
Plazomicin is a new intravenous (IV) aminoglycoside indicated for the treatment of Complicated Urinary Tract Infections (CUTI), including pyelonephritis.
"The introduction of plazomicin in India is an important step forward in bringing solutions that address the evolving healthcare challenges of our time," Cipla MD and Global CEO Umang Vohra said in a statement.
The company's focus remains on developing a robust antimicrobial portfolio, forging partnerships with thought leaders and industry alliances to ensure global access to antimicrobial drugs for a healthier life, he added.
Cipla USA, a subsidiary of Cipla, holds the patent for plazomicin sulfate, an intravenous aminoglycoside administered once daily.
The company possesses global rights for this molecule, excluding Greater China.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 17.90 ( -3.35)
- 166585989
- Alstone Textiles
- 0.75 (+ 8.70)
- 47681821
- GTL Infrastructure
- 3.27 (+ 4.81)
- 44040612
- Visagar Financial
- 0.91 (+ 12.35)
- 29755394
- YES Bank Ltd.
- 23.70 (+ 0.77)
- 22163699
MORE NEWS
![Indian Economy...](https://im.rediff.com/80-80/money/2020/nov/22economy.jpg)
Indian Economy Growth: Exports, Manufacturing &...
Mumbai, June 30 (PTI) Healthy increase in the country's exports, improvement in the...
![India Launches...](https://im.rediff.com/80-80/news/2020/jul/imports-o.jpg)
India Launches Anti-Dumping Probe on Glass...
New Delhi, June 30 (PTI) India has initiated an anti-dumping probe into the import of...
![IBBI Launches...](https://im.rediff.com/80-80/money/2020/dec/16insolvency.jpg)
IBBI Launches Electronic Forms for Liquidation...
New Delhi, Jun 30 (PTI) To ease the compliance burden for insolvency professionals, and...